At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Tobemstomig, Pembrolizumab, and 3 other interventions for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 182 participants across 50 sites in 11 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Study Details
Timeline
Interventions
Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
Participants will receive IV pembrolizumab four 21-day cycles
Participants will receive IV paclitaxel Q3W for four 21-day cycles
Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
Participants will receive IV carboplatin Q3W for four 21-day cycles